[
  {
    "ts": null,
    "headline": "Is ISRG's 20% Procedure Growth the New Normal or a Peak?",
    "summary": "ISRG posts 20% Q3 procedure growth as da Vinci and Ion volumes accelerate, but investors question if product cycles and timing effects can sustain it.",
    "url": "https://finnhub.io/api/news?id=5ff50d4b51ac9fb5c32c9365a696e4e8abbe3649b6ab3ca1621af605d6db184d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766751420,
      "headline": "Is ISRG's 20% Procedure Growth the New Normal or a Peak?",
      "id": 137908314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "ISRG posts 20% Q3 procedure growth as da Vinci and Ion volumes accelerate, but investors question if product cycles and timing effects can sustain it.",
      "url": "https://finnhub.io/api/news?id=5ff50d4b51ac9fb5c32c9365a696e4e8abbe3649b6ab3ca1621af605d6db184d"
    }
  }
]